Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $0.73.

  • Rhythm Pharmaceuticals' Debt to Equity changed N/A to $0.73 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.73, marking a year-over-year change of. This contributed to the annual value of $5.05 for FY2024, which is 70824.61% up from last year.
  • Rhythm Pharmaceuticals' Debt to Equity amounted to $0.73 in Q3 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Debt to Equity peaked at $5.78 during Q1 2025, and registered a low of -$9.22 during Q2 2025.
  • In the last 3 years, Rhythm Pharmaceuticals' Debt to Equity had a median value of $0.73 in 2025 and averaged $0.59.
  • Within the past 5 years, the most significant YoY rise in Rhythm Pharmaceuticals' Debt to Equity was 70824.61% (2024), while the steepest drop was 70824.61% (2024).
  • Rhythm Pharmaceuticals' Debt to Equity (Quarter) stood at $0.63 in 2023, then skyrocketed by 708.25% to $5.05 in 2024, then tumbled by 85.51% to $0.73 in 2025.
  • Its last three reported values are $0.73 in Q3 2025, -$9.22 for Q2 2025, and $5.78 during Q1 2025.